Inhibitory effect of dietary atorvastatin and celecoxib together with voluntary running wheel exercise on the progression of androgen-dependent LNCaP prostate tumors to androgen independence

Experimental and Therapeutic Medicine

Volumn 2, Issue 2, 2011, Pages 221-228

  Zheng, Xi ^a,c   Cui, Xiao Xing ^a   Gao, Zhi ^a   Zhao, Yang ^a   Shi, Yi ^a   Huang, Mou Tuan ^a   Liu, Yue ^a   Wagner, George C ^b   Lin, Yong ^c,d   Shih, Weichung Joe ^c,d   Rao, Chinthalapally V ^e   Yang, Chung S ^a,c   Conney, Allan H ^a,c  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^e UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Androgen depletion; Exercise; Progression; Prostate cancer

Indexed keywords

2 HYDROXYATORVASTATIN; 4 HYDROXYATORVASTATIN; ANDROGEN; ATORVASTATIN; CARBOXYCELECOXIB; CELECOXIB; DRUG METABOLITE; HYDROXYCELECOXIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CANCER SIZE; CELL STRAIN LNCAP; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIETARY INTAKE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; EXERCISE; HUMAN; HUMAN CELL; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PROSTATE TUMOR; TUMOR GROWTH;

EID: 79551638178     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.203     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Heinlein CA and Chang C: Androgen receptor in prostate cancer. Endocr Rev 25: 276-308, 2004.
3. Loblaw DA, virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, vogelzang NJ, Wade JL III, Bennett CL, Scher HI; American Society of Clinical oncology: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical oncology practice guideline. J Clin oncol 25: 1596-1605, 2007.
4. Petrylak DP, Tangen CM, lussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004.
5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
6. Zheng X, Cui XX, Gao Z, et al: Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer prev res 3: 114-124, 2010.
7. Zheng X, Cui XX, Avila GE, Huang MT, Liu Y, patel J, Kong AN, Paulino R, Shih WJ, Lin Y, Rabson AB, Reddy BS and Conney AH: Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin Cancer Res 13: 5480-5487, 2007.
8. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ and Calle EE: Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 16: 2213-2217, 2007.
9. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC Jr, Amling CL and Freedland SJ: Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer hospital (SEARCH) Database. Cancer 116: 3389-3398, 2010.
10. Murtola T, Tammela TLJ, Lahtela J and Auvinen A: Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 16: 2226-2232, 2007.
11. Platz EA, Leitzmann MF, Visvanathan K, et al: Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98: 1819-1825, 2006.
12. Bañez LL, Klink JC, Jayachandran J, Lark AL, Gerber L, Hamilton RJ, Masko EM, Vollmer RT and Freedland SJ: Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. Cancer Epidemiol Biomarkers Prev 19: 722-728, 2010.
13. Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G and Witte JS: COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer 97: 557-561, 2007.
14. Stock D, Groome PA and Siemens DR: Inflammation and prostate cancer: a future target for prevention and therapy? Urol Clin North Am 35: 117-130, 2008.
15. Cerhan JR, Torner JC, Lynch CF, et al: Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States). Cancer Causes Control 8: 229-238, 1997.
16. Wannamethee SG, Shaper AG and Walker M: Physical activity and risk of cancer in middle-aged men. Br J Cancer 85: 1311-1316, 2001.
17. Friedenreich CM, McGregor SE, Courneya KS, Angyalfi SJ and Elliott FG: Case-control study of lifetime total physical activity and prostate cancer risk. Am J Epidemiol 159: 740-749, 2004.
18. Patel AV, Rodriguez C, Jacobs EJ, Solomon L, Thun MJ and Calle EE: recreational physical activity and risk of prostate cancer in a large cohort of US men. Cancer Epidemiol Biomarkers Prev 14: 275-279, 2005.
19. Nilsen TI, Romundstad PR and Vatten LJ: recreational physical activity and risk of prostate cancer: a prospective population-based study in Norway (the HUNT study). int J Cancer 119: 2943-2947, 2006.
20. Orsini N, Bellocco R, Bottai M, Pagano M, Andersson So, Johansson JE, Giovannucci E and Wolk A: A prospective study of lifetime physical activity and prostate cancer incidence and mortality. Br J Cancer 101: 1932-1938, 2009.
21. Antonelli JA, Jones LW, Bañez LL, Thomas JA, Anderson K, Taylor LA, Gerber L, Anderson T, Hoyo C, grant D and Freedland SJ: Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy. J urol 182: 2226-2231, 2009.
22. Zheng X, Cui XX, Huang MT, Liu Y, Shih WJ, Lin Y, Lu YP, Wagner GC and Conney AH: Inhibitory effect of voluntary running wheel exercise on the growth of human pancreatic Panc-1 and prostate PC-3 xenograft tumors in immunodeficient mice. oncol rep 19: 1583-1588, 2008.
23. Lindsey JK: Models for Repeated Measurments. Claredon Press, Oxford, 1993.
24. Zhang JY, Wang Y, Dudkowski C, Yang D, Chang M, Yuan J, Paulson SK and Breau AP: Characterization of metabolites of celecoxib in rabbits by liquid chromatography/tandem mass spectrometry. J Mass Spectrom 35: 1259-1270, 2000.
25. Black AE, Hayes RN, Roth BD, Woo P and Woolf TF: Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab dispos 27: 916-923, 1999.
26. Lins RL, Matthys KE, Verpooten GA, Peeters PC, Dratwa M, Stolear JC and Lameire NH: Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercho-lesterolaemic haemodialysis patients. Nephrol Dial Transplant 18: 967-976, 2003.
27. Reddy BS, Wang CX, Kong AN, Khor To, Zheng X, Steele VE, Kopelovich L and Rao CV: prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer res 66: 4542-4546, 2006.
28. Reddy BS, Sugie S and Lowenfels A: Effect of voluntary exercise on azoxymethane-induced colon carcinogenesis in male F344 rats. Cancer res 48: 7079-7081, 1988.
29. Cohen LA, Choi K, Backlund JY, Harris R and Wang CX: Modulation of N-nitrosomethylurea induced mammary tumori-genesis by dietary fat and voluntary exercise. In Vivo 5: 333-344, 1991.
30. thompson HJ: Effects of physical activity and exercise on experimentally -induced mammary carcinogenesis. Breast Cancer Res Treat 46: 135-141, 1997.
31. Michna L, Wagner GC, Lou YR, Xie JG, peng QY, Lin Y, Carlson K, Shih WJ, Conney AH and Lu YP: Inhibitory effects of voluntary running wheel exercise on UVB-induced skin carcinogenesis in SKH-1 mice. Carcinogenesis 27: 2108-2115, 2006.
32. Beavers KM, Brinkley TE and Nicklas BJ: Effect of exercise training on chronic inflammation. Clin Chim Acta 411: 785-793, 2010.
33. Mathur N and Pedersen BK: Exercise as a mean to control low-grade systemic inflammation. Mediators Inflamm: Jan. 11, 2009 (E-pub ahead of print).
34. Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ and posvar EL: Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-COA reductase, in healthy subjects. Clin Pharmacol Ther 60: 687-695, 1996.
35. Lennernas H: Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42: 1141-1160, 2003.
36. Davies NM, McLachlan AJ, Day RO and Williams KM: Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 38: 225-242, 2000.